News | May 26, 2022
Strides Pharma Science Q4FY22 consolidated PAT at Rs. 29.21 Cr
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
The company has posted net loss of Rs. 460.21 crores for the Financial Year ended March 31, 2022.
The AI and technology upgrades allow doctors to choose their medical speciality and even spelling preferences to set their own speech model
The aim is to provide further insights into patients' lives in the effort to deliver better outcomes for people with psoriatic arthritis (PsA)
ICICI Direct expects revenue CAGR of 35.6% over FY22-FY24E mainly due to the consolidation of Viatris business and they expect EBITDA margin expansion of 230bps and earnings CAGR of 64.8% over FY22-FY24E
Strategic partnership will develop a digital transformation roadmap and create opportunities for co-innovation in healthcare technologies
For the third straight year, Lumenis wins an award recognizing outstanding medical companies and technologies
By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry
New block enhances the company's global capabilities in Oral Solid Dosage (OSD) Forms, increasing total plant capacity to 4.5 billion doses
The company has posted net profit of Rs.605.05 crores for the Financial Year ended March 31, 2022
The company has posted net profit of Rs.884.08 crores for the Financial Year ended March 31, 2022.
Subscribe To Our Newsletter & Stay Updated
